Skip to main content
. 2021 Aug 5;139(9):1–10. doi: 10.1001/jamaophthalmol.2021.2809

Figure 1. Study Design.

Figure 1.

One eye was assessed per participant. Aflibercept 2q16 group: intravitreal injection of aflibercept, 2 mg, every 16 weeks after 3 initial monthly doses and one 8-week interval. Aflibercept 2q8/PRN group: intravitreal injection of aflibercept, 2 mg every 8 weeks after 5 initial monthly doses, with pro re nata (PRN) dosing beginning at week 56. DRSS indicates Diabetic Retinopathy Severity Scale; NPDR, nonproliferative diabetic retinopathy; and PRN, pro re nata.